Since its inception in 2003, DNDi has built the most robust portfolio ever developed for kinetoplastid diseases (sleeping sickness, leishmaniasis, Chagas disease). True to its mission of responding to the unmet needs of neglected patients, DNDi, while maintaining a full commitment to kinetoplastid diseases, has expanded its portfolio in 2011 to include two new disease areas: paediatric HIV and helminth infections, with a specific focus on filariasis. DNDi will conclude its malaria activities, including technology transfer and sustained access activities, by 2014.
Anon. A Needs-Driven Collaborative R&D Model for Neglected Diseases. 6 pp. [2011 R&D Portfolio]